The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Therapeutic Pipeline Program, 2015Alpha4Beta2 Nicotinic Agonist for Treatment of L-Dopa Refractory Gait and Balance Disorders in Parkinson Disease
Study Rationale:
Gait and balance problems, particularly falls, are common and disabling symptoms in Parkinson disease (PD), and do not improve markedly with existing treatments. Studies have indicated... -
Target Validation, 2015Validating the Neuroprotective Enzyme ACMSD as a Novel Therapeutic Target in Parkinson's Disease by Viral Vector-Mediated Overexpression
Study Rationale:
A number of genetic studies have linked variation in the enzyme aminocarboxy-muconate semialdehyde decarboxylase (ACMSD) with a risk for Parkinson’s... -
Improved Biomarkers and Clinical Outcome Measures, 2015Defining a PD-specific Breath Fingerprint of Underlying Inflammatory and Neurodegenerative Processes
Study Rationale:
Breath analysis has the potential to be a powerful non-invasive screening tool to help a clinician determine the need for additional more invasive tests, a tool...
-
Research Grant, 2015VPAC2 Agonists Neuroprotective and Anti-inflammatory Effects in Parkinson's Disease
Study Rationale:
The adaptive and innate immune responses play intricate roles in modulating neuroinflammation and may be harnessed for neuroprotection from Parkinson’s disease. We... -
Therapeutic Pipeline Program, 2015Improving Access to Depression Care in Parkinson’s Disease: A Telehealth Approach
Study Rationale:
There is a critical need for treatments that address depression and barriers to care among the approximately 5 million people living with Parkinson’s disease (PD)... -
Biomarker Development, 2015Comparison of Pre- and Post-mortem Cerebrospinal Fluid Levels of Proteins and Lipids
Study Rationale:
Alpha-synuclein aggregation in the brain is the main pathology of Parkinson’s disease (PD). Cerebrospinal fluid (CSF) levels of alpha-synuclein are lower in PD. It...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.